Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: A study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412

Neurology

Volumn 48, Issue 4, 1997, Pages 810-816

  Llewellyn Smith, N ^a,b   Lai, M ^c   Miller, D H ^b   Rudge, P ^a   Thompson, A J ^b   Cuzner, M L ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c WELLINGTON HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

OKT 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030950930     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.4.810     Document Type: Article

References (33)

1. Raine CS. Multiple sclerosis: a pivotal role for the T cell in lesion development. Neuropathol Appl Neurobiol 1991:17:265-274.
2. Hauser SL, Reinherz EL, Hoban CJ, Schlossmann SF, Weiner HL. CSF cells in multiple sclerosis: monoclonal antibody analysis and relationship to peripheral blood T-cell subsets. Neurology 1983:33:575-579.
3. Wekerle H, Kojima K, Lannes-Vieira J, Lassman H, Linington C. Animal models. Ann Neurol 1994:36 (suppl):S47-S53.
4. The INFB Multiple Sclerosis Study Group. Interferon β1B is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomised, placebo-controlled trial. Neurology 1993:43:655-661.
5. Lindsey JW, Hodgkinson S, Mehta R, Mitchell D, Enzmann D, Steinman L. Repeated treatment with chimaeric anti-CD4 antibody in multiple sclerosis. Ann Neurol 1994:36:183-189.
6. O Neill JK, Baker D, Davison AN, et al. Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies. J Neuroimmunol 1993:45:1-14.
7. Dalesandro MR, Pak KY, Tam S, et al. Effects of isotype and Fc region on in vitro function of a mouse/human CD4 antibody. Int Immunol 1993:5:283-291.
8. Lindsey JW, Hodgkinson S, Mehta R, et al. Phase I clinical trial of chimaeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 1994:44:413-419.
9. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MRI-monitored phase III trial (Paper submitted).
10. Grimaud J, Lai M, Thorpe JW, et al. Evaluation of a computer assisted quantification of MS lesions in cranial MRI [abstract]. Proc Soc Magn Reson 1995:1:283.
11. Centers for Disease Control. Guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus infection. MMWR 1992:41:RR-8.
12. National Committee for Clinical Laboratory Standards. Clinical applications of flow cytometry: quality assurance and immunophenotyping of peripheral blood lymphocytes; tentative guideline. NCCLS 1992 Document H42-T. (ISBN 1-56238-155-5.)
13. Bofill M, Janossy G, Lee CA, et al. Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-I diagnosis. Clin Exp Immunol 1992:88:43-52.
14. Reichert T, DeBruyere M, Deneys V, et al. Lymphocyte subset reference ranges in adult caucasians. Clin Immunol Immunopathol 1991:60:190-208.
15. Lewis SM, Verwilghen RL, ed. Quality assurance in haematology: the use of reference values. London: Bailliere Tindall, 1988.
16. Eoli M, Ferrarini M, Dufour A, et al. Presence of T-cell subset abnormalities in newly diagnosed cases of multiple sclerosis and relationships with short-term clinical activity. J Neurol 1992:240:79-82.
17. Scott TF, McKolonis J, Rothfus W, Cottington E. Lymphocyte subsets in relapsing-remitting multiple sclerosis: a longitudinal study of B lymphocytes and T lymphocytes. Neurol Res 1994:6:385-388.
18. Moreland LW, Pratt PW, Sanders ME, Koopman WJ. Experience with a chimaeric monoclonal anti-CD4 antibody in the treatment of refractory rheumatoid arthritis. Clin Exp Rheumatol 1993:11 (suppl 8):S153-S159.
19. van der Lubbe PA, Reiter C, Miltenburg AM, et al. Treatment of rheumatoid arthritis with a chimaeric CD4 monoclonal antibody (cM-T412): immunopharmacological aspects and mechanisms of action. Scand J Immunol 1994:39:286-294.
20. Wineman JP, Gilmore GL, Gritzmacher C, Torbett BE, Muller-Sieburg C. CD4 is expressed on murine pluripotent haematopoietic stem cells. Blood 1992:80:1717-1724.
21. Kabelitz D, Pohl T, Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral lymphocytes. Immunol Today 1993:14:338-9.
22. lck plays a key role in transducing apoptotic signals in T cells. FEBS Lett 1995:363:101-104.
23. Chace J, Cowdery JS, Field EH. Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially depletes resting, naive CD4 cells and spares activated CD4 cells. J Immunol 1994: 152:405-412.
24. Horneff G, Sack U, Kalden JR, Emmrich F, Burmester GR. Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin, and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol 1993:91:207-213.
25. Capra R, Marciano N, Cotti Cometti V, et al. Immunological and gadolinium-DTPA MRI evaluation of relapsing-remitting multiple sclerosis. Acta Neurol Scand 1992:86:342-345.
26. Bach MA, Martin C, Cesaro P, Eisenbaum JF, Degos JD. T cell subsets in multiple sclerosis. J Neuroimmunol 1985:7: 331-343.
27. Compston A. Lymphocyte subpopulations in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1983:46: 105-114.
28. Thompson AJ, Brazil J, Whelan CA, Martin EA, Hutchinson M, Feighery C. Peripheral blood T lymphocyte changes in multiple sclerosis: a marker of disease progression rather than of relapse. J Neurol Neurosurg Psychiatry 1986:49:905-912.
29. Zabriskie JB, Mayer L, Fu SM, Yeadon C, Cam V, Plank C. T cell subsets in multiple sclerosis: lack of correlation between helper and suppressor T cells and the clinical state. J Clin Immunol 1985:5:7-12.
30. Strauss K, Hulstaert F, Deneys V, Mazzon AM, Hannet I, De Bruyere M. The immune profile of multiple sclerosis: T lymphocyte effects predominate over all other factors in cyclophosphamide-treated patients. J Neuroimmunol 1995:63: 133-142.
31. Munschauer FE, Hartrich LA, Stewart CC, Jacobs L. Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little disability as compared to controls. J Neuroimmunol 1995:62:177-181.
32. Salonen R, Ilonen J, Jagerroos H, Syrjala H, Nurmi T, Reunanen M. Lymphocyte subsets in the cerebrospinal fluid in active multiple sclerosis. Ann Neurol 1989:25:500-502.
33. Chofflon M, Weiner HL, Morimoto C, Hafler DA. Decrease of suppressor inducer (CD4+2H4+) T cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 1989:25:494-499.